Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jul 9;222(Suppl 1):S31-S40.
doi: 10.1093/infdis/jiaa213.

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

Laura M Smeaton  1 , Emma M Kileel  2 , Beatriz Grinsztejn  3 , Edward M Gardner  4 , Kate Starr  5 , Melissa L Murry  6 , Patrice Desvigne-Nickens  7 , Beverly Alston-Smith  8 , Myron A Waclawiw  7 , Katharine Cooper-Arnold  7 , José V Madruga  9 , Shashi Sangle  10 , Kathleen V Fitch  2 , Markella V Zanni  2 , Pamela S Douglas  11 , Heather J Ribaudo  1 , Steven K Grinspoon  2 , Karin L Klingman  8
Affiliations
Randomized Controlled Trial

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum

Laura M Smeaton et al. J Infect Dis. .

Abstract

Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.

Keywords: HIV; cardiovascular; gender identity; gender-affirming hormone treatment; transgender spectrum.

PubMed Disclaimer

References

    1. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health 2019; 109:e1–8. - PMC - PubMed
    1. Baral SD, Poteat T, Strömdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis 2013; 13:214–22. - PubMed
    1. USTS-Full-Report-FINAL The Report of the 2015 U.S. Transgender Survey. Available at: https://www.transequality.org/sites/default/files/docs/USTS-Full-Report-.... Accessed 10 January 2020.
    1. King WM, Restar A, Operario D. Exploring multiple forms of intimate partner violence in a gender and racially/ethnically diverse sample of transgender adults. J Interpers Violence 2019; 0886260519876024. - PubMed
    1. Wansom T, Guadamuz TE, Vasan S. Transgender populations and HIV: unique risks, challenges and opportunities. J Virus Erad 2016; 2:87–93. - PMC - PubMed

Publication types

LinkOut - more resources